Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

Tanguy Sewiert, MD
Published: Friday, May 29, 2015



Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Seiwert discusses a recent expansion cohort of 135 patients with recurrent metastatic head and neck cancer treated with pembrolizumab as a single agent. Patients had a poor prognosis and were heavily pretreated.

Results showed that pembrolizumab achieved response in 25% of patients. While this is early data, Seiwert explains it is promising for treatment of the disease. Few patients, he adds, had severe adverse events.

<<< View more from the 2015 ASCO Annual Meeting



Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Seiwert discusses a recent expansion cohort of 135 patients with recurrent metastatic head and neck cancer treated with pembrolizumab as a single agent. Patients had a poor prognosis and were heavily pretreated.

Results showed that pembrolizumab achieved response in 25% of patients. While this is early data, Seiwert explains it is promising for treatment of the disease. Few patients, he adds, had severe adverse events.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x